Neisvac-C

N. meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It is used to prevent invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk.

GNH USA supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and vaccination centres worldwide.

Neisvac-C is a conjugate vaccine that targets the meningococcal group C pathway to prevent serious bacterial infection.

- Invasive meningococcal disease (serogroup C): provides active immunity to prevent meningitis and septicemia caused by N. meningitidis group C. - Adolescents and young adults: reduces risk of serogroup C infection in this high‑risk age group. - Outbreak control and travel: used in vaccination campaigns to curb serogroup C outbreaks and protect travelers to endemic areas.

Neisvac-C may cause a range of post‑vaccination reactions, most of which are mild and self‑limiting.

Common Side Effects: - Injection site pain: soreness or tenderness at the injection site. - Redness or swelling: localized erythema or edema. - Fever: low‑grade temperature rise within 24‑48 hours. - Headache: mild to moderate headache after vaccination. - Fatigue: transient tiredness or malaise. - Myalgia: muscle aches in the days following injection.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder with muscle weakness. - Seizures: occasional convulsive episodes, especially in infants. - Hypotension: sudden drop in blood pressure post‑injection. - Immune‑mediated thrombocytopenia: low platelet count with bleeding risk. - Severe local reaction: extensive necrosis or abscess at the injection site.

Before administering Neisvac-C, consider the following safety measures.

- Allergy assessment: verify no known hypersensitivity to any vaccine component. - Acute illness: postpone vaccination in persons with moderate or severe febrile illness. - Observation: monitor for at least 15 minutes after injection for immediate hypersensitivity. - Concurrent vaccines: separate administration from live vaccines by at least 4 weeks. - Pregnancy and lactation: use only if benefits outweigh potential risks, as data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac-C may interact with other agents that affect immune response or vaccine efficacy.

Major Interactions (Avoid): - Other meningococcal conjugate vaccines: avoid simultaneous use to prevent antigenic interference. - Live bacterial vaccines (e.g., oral typhoid): avoid co‑administration within 4 weeks.

Moderate Interactions (Monitor Closely): - Immunosuppressive agents (corticosteroids, chemotherapy): may diminish antibody response. - Intravenous immunoglobulin or blood products: may interfere with vaccine efficacy if given within 4 weeks. - Antipyretics: may reduce fever but do not affect immunogenicity.